Physician profile
Bryan Randolph
NPI 1649276007
$4,975.87
in general payments reported to CMS, 2019-2025
27 companies · $862 in 2025
The $862 reported for 2025 was more than what 77% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $255 · 2021: $1,603 · 2022: $450 · 2023: $429 · 2024: $578 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,069.15 | 2021 | |
| Mimedx Group, INC. | $865.05 | 2024-2025 | |
| Abbvie INC. | $634.40 | 2021-2025 | |
| Melinta Therapeutics, LLC | $565.88 | 2019-2025 | Kimyrsa |
| Paratek Pharmaceuticals, INC. | $402.05 | 2020-2025 | Nuzyra |
| Organogenesis INC. | $235.41 | 2020-2023 | Puraply |
| Allergan, INC. | $208.22 | 2019-2020 | |
| Smith+Nephew, INC. | $177.38 | 2019-2023 | Collagenase Santyl, Regranex |
| Wright Medical Technology, INC. | $122.43 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $90.68 | 2022-2024 | Jublia |
| Kerecis Limited | $87.49 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Averitas Pharma INC. | $79.35 | 2025 | Qutenza |
| Triad Life Sciences INC. | $78.62 | 2022 | |
| Sanara Medtech INC. | $44.75 | 2021 | |
| Treace Medical Concepts, INC. | $41.97 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $41.21 | 2019-2020 | |
| Horizon Therapeutics Plc | $39.92 | 2019 | |
| Nevro Corp. | $35.55 | 2022 | |
| Bioventus LLC | $27.57 | 2022 | |
| Convatec INC. | $24.22 | 2023 | |
| Merck Sharp & Dohme LLC | $21.96 | 2019 | |
| Ibsa Pharma INC. | $19.02 | 2023 | Tirosint, Licart |
| Curonix LLC | $17.21 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pfizer INC. | $16.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.47 | 2022 | |
| Arteriocyte Medical Systems, INC. | $10.12 | 2019 | |
| Grt US Holding, INC. | $6.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.